Emerging drugs for allergic conjunctivitis

Bibliography

• Leonardi A, Bogacka E, Fauquert JL, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 2012;67(11):1327-37
   PubMed Web of Science ®Google Scholar
• Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol 2011;11(5):477-82
   PubMed Web of Science ®Google Scholar
• Sy H, Bielory L. Atopic keratoconjunctivitis. Allergy Asthma Proc 2013;34(1):33-41
   PubMed Web of Science ®Google Scholar
• Nathan H, Meltzer EO. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1999;99:S808-14
   Web of Science ®Google Scholar
• Hesselmar B, Aberg B, Eriksson B, Aberg N. Allergic rhinoconjunctivitis, eczema, and sensitization in two areas with differing climates. Pediatr Allergy Immunol 2001;12(4):208-15
   PubMed Web of Science ®Google Scholar
• Anderson DF, MacLeod JD, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy 1997;27(9):1060-6
   PubMed Web of Science ®Google Scholar
• KleinJan A, McEuen AR, Dijkstra MD, et al. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000;106(4):677-86
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Tominaga T, Yakura K, et al. Conjunctival mast cell as a mediator of eosinophilic response in ocular allergy. Mol Vis 2008;14:1525-32
   PubMed Web of Science ®Google Scholar
• Bacon AS, McGill JI, Anderson DF, et al. Adhesion molecules and relationship to leukocyte levels in allergic eye disease. Invest Ophthalmol Vis Sci 1998;39(2):322-30
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Nakamura T, Ohbayashi M, et al. Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade. Int Immunol 2009;21(2):187-201
   PubMed Web of Science ®Google Scholar
• Fukuda K, Kuo CH, Morohoshi K, et al. The murine CCR3 receptor regulates both eosinophilia and hyperresponsiveness in IgE-mediated allergic conjunctivitis. Br J Ophthalmol 2012;96(8):1132-6
   PubMed Web of Science ®Google Scholar
• Ueta M, Matsuoka T, Narumiya S, et al. Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis. J Allergy Clin Immunol 2009;123(2):466-71
   PubMed Web of Science ®Google Scholar
• Möller C, Björkstén B, Nilsson G, et al. The precision of the conjunctival provocation test. Allergy 1984;39(1):37-41
   PubMed Web of Science ®Google Scholar
• Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 2013;6(1):17
   PubMedGoogle Scholar
• Virchow JC, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ 2011;14(3):305-14
   PubMedGoogle Scholar
• Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11(1):17-33
   PubMed Web of Science ®Google Scholar
• Smith AF, Pitt AD, Rodriguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12(4):233-42
   PubMed Web of Science ®Google Scholar
• Palmares J, Delgado L, Cidade M, et al. Season Study Group. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol 2010;20(2):257-64
   PubMed Web of Science ®Google Scholar
• Ghazala L, Schmid F, Helbling A, et al. Efficacy of house dust mite and allergen impermeable encasings in patients with house dust mite allergy. Allergologie 2004;27:26-34
   Web of Science ®Google Scholar
• Ozturk AB, Celebioglu E, Karakaya G, et al. Protective efficacy of sunglasses on the conjunctival symptoms of seasonal rhinitis. Int Forum Allergy Rhinol 2013;3:1001-6
   Google Scholar
• Fujishima H, Fukagawa K, Takano Y, et al. The early efficacy of topical levocabastine in patients with allergic conjunctivitis. Allergol Int 2006;55(3):301-3
   PubMedGoogle Scholar
• Orfeo V, Vardaro A, Lena P, et al. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur J Ophthalmol 2002;12(4):262-6
   PubMed Web of Science ®Google Scholar
• Meier EJ, Torkildsen GL, Gow JA, et al. Bepotastine Besilate Ophthalmic Solutions Study Group. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc 2012;33(3):265-74
   PubMed Web of Science ®Google Scholar
• Williams JI, Kennedy KS, Gow JA, et al. Bepotastine Besilate Ophthalmic Solutions Study Group. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther 2011;27(4):385-93
   PubMed Web of Science ®Google Scholar
• Carr WW, Nayak AS, Ratner PH, et al. Bepotastine Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc 2013;34(3):247-54
   PubMed Web of Science ®Google Scholar
• Williams PB, Crandall E, Sheppard JD. Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clin Ophthalmol 2010;4:993-1001
   PubMedGoogle Scholar
• Ohno S; Olopatadine Study Group. A multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitis. Nihon Ganka Gakkai Zasshi 2012;116(12):1123-9
   PubMedGoogle Scholar
• Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin 2011;27(3):623-31
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004;26(1):29-34
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000;84(5):504-8
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995;95(2):612-21
   PubMed Web of Science ®Google Scholar
• Buscaglia S, Paolieri F, Catrullo A, et al. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro. Clin Exp Allergy 1996;26(10):1188-96
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27(2):182-91
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001;87(5):424-9
   PubMed Web of Science ®Google Scholar
• Woerly G, Loiseau S, Loyens M, et al. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003;58(5):397-406
   PubMed Web of Science ®Google Scholar
• O'Brien TP. Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol 2013;13(5):543-9
   PubMed Web of Science ®Google Scholar
• Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30(1):10-13
   PubMedGoogle Scholar
• Gong L, Sun X, Qu J, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther 2012;34(6):1259-72
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008;100(3):272-9
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Rong SS, et al. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology 2013;120(11):2197-20
   PubMed Web of Science ®Google Scholar
• Kawashima T, Iwamoto I, Nakagawa N, et al. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol 1994;103(4):405-9
   PubMed Web of Science ®Google Scholar
• Shulman DG. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. Adv Ther 2003;20(1):31-40
   PubMed Web of Science ®Google Scholar
• Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995;102(2):310-16
   PubMed Web of Science ®Google Scholar
• Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol 1998;8(4):207-16
   PubMed Web of Science ®Google Scholar
• Goldschmidt P, Luyckx J. Effects of lodoxamide (LOD), disodium cromoglycate (DSCG) and N-acetyl-aspartyl-glutamate sodium salt (NAAGA) on ocular active anaphylaxis. Allerg Immunol (Paris) 1996;28(4):124-6
   PubMedGoogle Scholar
• Leonardi A, Bremond-Gignac D, Bortolotti M, et al. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 2007;91(12):1662-6
   PubMed Web of Science ®Google Scholar
• Duzman E, Warman A, Warman R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann Ophthalmol 1986;18(1):28-31
   PubMed Web of Science ®Google Scholar
• Figus M, Fogagnolo P, Lazzeri S, et al. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. Eur J Ophthalmol 2010;20(5):811-18
   PubMed Web of Science ®Google Scholar
• Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003;81(4):378-82
   PubMedGoogle Scholar
• Celik T, Turkoglu EB. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis. Curr Eye Res 2014;39(1):42-6
   PubMed Web of Science ®Google Scholar
• Shulman DG, Amdahl L, Washington C, et al. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Ther 2003;25(4):1096-106
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62(8):943-8
   PubMed Web of Science ®Google Scholar
• Yacoub MR, Colombo G, Marcucci F, et al. Effects of sublingual immunotherapy on allergic inflammation: an update. Inflamm Allergy Drug Targets 2012;11(4):285-91
   PubMedGoogle Scholar
• Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjuntivits and asthma. J Am Med Assoc 2013;309:1278-88
   PubMed Web of Science ®Google Scholar
• Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma; a systematic review. Laryngoscope 2014;124(3):616-27
   PubMed Web of Science ®Google Scholar
• Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: cochrane systematic review and meta-analysis. Clin Exp Allergy 2011;41(9):1263-72
   PubMed Web of Science ®Google Scholar
• Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013;131(6):1155-67
   PubMed Web of Science ®Google Scholar
• Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 2013;13(6):656-62
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Vighi G, Ridolo E. Systematic reviews and heterogeneity. Ann Allergy Asthma Immunol 2013;111(4):306
   PubMed Web of Science ®Google Scholar
• Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11(5):471-6
   PubMed Web of Science ®Google Scholar
• Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA 2013;310(16):1721-9
   PubMed Web of Science ®Google Scholar
• Kamali A, Whitworth JA, Ruberantwari A, et al. Causes and prevalence of non-vision impairing ocular conditions among a rural adult population in Uganda. Ophthalmic Epidemiol 1999;6(1):41-8
   PubMedGoogle Scholar
• Ikeda H, Tsukamoto H, Sato E, et al. Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. Ophthalmic Epidemiol 2004;11(1):35-42
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ 2011;14(3):305-14
   PubMedGoogle Scholar
• Incorvaia C, Ariano R, Berto P, et al. Economic aspects of sublingual immunotherapy. Int J Immunopathol Pharmacol 2009;22(4 Suppl):27-30
   PubMedGoogle Scholar
• Hankin CS, Cox L, Bronstone A, et al. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 2013;131(4):1084-91
   PubMed Web of Science ®Google Scholar
• Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31(8):1295-302
   PubMed Web of Science ®Google Scholar
• Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjuntivits and asthma. JAMA 2013;309:1278-88
   PubMed Web of Science ®Google Scholar
• Köberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2011;11(3):192-9
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310
   PubMed Web of Science ®Google Scholar
• Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 2004;48(6):587-90
   PubMed Web of Science ®Google Scholar
• Fujishima H, Fukagawa K, Takano Y, et al. Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25(3):265-70
   PubMed Web of Science ®Google Scholar
• Li Z, Mu G, Chen W, et al. Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis. Cornea 2013;32(5):579-82
   PubMed Web of Science ®Google Scholar
• Schäcke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275(1-2):109-17
   PubMed Web of Science ®Google Scholar
• Shafiee A, Bucolo C, Budzynski E, et al. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 2011;52(3):1422-30
   PubMed Web of Science ®Google Scholar
• Cavet ME, Volhejn S, Harrington KL, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 2013;19:1515-25
   PubMed Web of Science ®Google Scholar
• Baiula M, Spartà A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-23
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Andoh T, Sakai K, Urashima M, et al. Involvement of leukotriene B4 in itching in a mouse model of ocular allergy. Exp Eye Res 2012;98:97-103
   PubMed Web of Science ®Google Scholar
• Gane J, Buckley R. Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2013;1(1):65-74
   Google Scholar
• Horner AA, Redecke V, Raz E. Toll-like receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 2004;4(6):555-61
   PubMed Web of Science ®Google Scholar
• Chung SH, Choi SH, Cho KJ, et al. Toll-like receptor 4 signalling attenuates experimental allergic conjunctivitis. Clin Exp Immunol 2011;164(2):275-81
   PubMed Web of Science ®Google Scholar
• Magone MT, Chan CC, Beck L, et al. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000;30(7):1841-50
   PubMed Web of Science ®Google Scholar
• Fukushima A, Yamaguchi T, Ishida W, et al. TLR2 agonist ameliorates murine experimental allergic conjunctivitis by inducing CD4 positive T-cell apoptosis rather than by affecting the Th1/Th2 balance. Biochem Biophys Res Commun 2006;339(4):1048-55
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Melli V, et al. Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 2014;15(1):73-83
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505
   PubMed Web of Science ®Google Scholar
• Xue L, Gyles SL, Wettey FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 2005;175(10):6531-6
   PubMed Web of Science ®Google Scholar
• Pettipher R, Vinall SL, Xue L, et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340(2):473-82
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 2012;67(12):1572-9
   PubMed Web of Science ®Google Scholar
• Tani K, Ogushi F, Kido H, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000;67(4):585-9
   PubMed Web of Science ®Google Scholar
• Nabe T, Kijitani Y, Kitagawa Y, et al. Involvement of chymase in allergic conjunctivitis of guinea pigs. Exp Eye Res 2013;113:74-9
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105(46):17908-12
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129(5):1290-6
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124(5):997-1002
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129(1):128-35
   PubMed Web of Science ®Google Scholar
• Del Prete A, Loffredo C, Carderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh) 1994;72(5):631-4
   PubMed Web of Science ®Google Scholar
• Núñez JA, Cuesta U. Local conjunctival immunotherapy: the effect of dermatophagoides pteronyssinus local conjunctival immunotherapy on conjunctival provocation test in patients with allergic conjunctivitis. Allergol Immunopathol (Madr) 2000;28(6):301-6
   PubMedGoogle Scholar
• Kasetsuwan N, Chatchatee P, Reinprayoon U. Efficacy of local conjunctival immunotherapy in allergic conjunctivitis. Asian Pac J Allergy Immunol 2010;28(4):237-41
   PubMed Web of Science ®Google Scholar
• Semba CP, Swearingen D, Smith VL, et al. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults. J Ocul Pharmacol Ther 2011;27(1):99-104
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 2014;121:475-83
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128(6):1139-50
   PubMed Web of Science ®Google Scholar
• Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Allergy Clin Immunol 2012;12(5):510-16
   PubMed Web of Science ®Google Scholar
• Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005;10(3):505-20
   PubMedGoogle Scholar